Global Blood Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 2/6

Global Blood Therapeutics şirketinin toplam hissedar öz sermayesi $118.4M ve toplam borcu $581.9M olup, bu da borç-öz sermaye oranını 491.7% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $870.4M ve $752.1M dir.

Anahtar bilgiler

n/a

Borç/özkaynak oranı

n/a

Borç

Faiz karşılama oranı	n/a
Nakit	n/a
Eşitlik	n/a
Toplam yükümlülükler	n/a
Toplam varlıklar	n/a

Son finansal sağlık güncellemeleri

Global Blood Therapeutics (NASDAQ:GBT) Is Making Moderate Use Of Debt

Jun 07

Is Global Blood Therapeutics (NASDAQ:GBT) Using Too Much Debt?

Feb 24

Despite Lacking Profits Global Blood Therapeutics (NASDAQ:GBT) Seems To Be On Top Of Its Debt

Nov 03

Global Blood Therapeutics (NASDAQ:GBT) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Jul 08

Is Global Blood Therapeutics (NASDAQ:GBT) A Risky Investment?

Mar 18

Recent updates

Global Blood Therapeutics to expand access to its sickle cell disease treatment in Brazil

Jul 14

GBT begins phase 2/3 clinical trial of GBT601 to treat sickle cell disease

Jun 29

Global Blood Therapeutics: Powerhouse Of The Future

Jun 21

Global Blood Therapeutics (NASDAQ:GBT) Is Making Moderate Use Of Debt

Jun 07

Global Blood Therapeutics: Hitting A Growth Inflection

Apr 12

Global Blood Therapeutics: Changing My Strategy After Recent Earnings

Mar 12

Is Global Blood Therapeutics (NASDAQ:GBT) Using Too Much Debt?

Feb 24

Global Blood Therapeutics: Revisiting A Stellar Grower

Dec 25

IBI Research On Global Blood Therapeutics: Galvanized For Growth

Nov 30

Despite Lacking Profits Global Blood Therapeutics (NASDAQ:GBT) Seems To Be On Top Of Its Debt

Nov 03

Global Blood Therapeutics: It Might Be Time To Buy The Dip

Oct 24

Global Blood Therapeutics: Attempting To Classify The Investment

Aug 07

Global Blood Therapeutics (NASDAQ:GBT) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Jul 08

Shareholders May Not Be So Generous With Global Blood Therapeutics, Inc.'s (NASDAQ:GBT) CEO Compensation And Here's Why

Jun 12

Global Blood Therapeutics announces employment inducement grants

Jun 04

Global Blood Therapeutics: Increasing Specialization In SCD

May 09

Is Global Blood Therapeutics (NASDAQ:GBT) A Risky Investment?

Mar 18

Breakeven On The Horizon For Global Blood Therapeutics, Inc. (NASDAQ:GBT)

Feb 20

Did Business Growth Power Global Blood Therapeutics' (NASDAQ:GBT) Share Price Gain of 152%?

Jan 25

Have Insiders Been Buying Global Blood Therapeutics, Inc. (NASDAQ:GBT) Shares?

Dec 29

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: GBT 'nin kısa vadeli varlıkları ( $640.0M ) kısa vadeli yükümlülüklerini ( $93.1M ) aşıyor.

Uzun Vadeli Yükümlülükler: GBT 'un kısa vadeli varlıkları ( $640.0M ) uzun vadeli yükümlülüklerini ( $659.0M ) karşılamamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: GBT 'nin net borç/öz sermaye oranı ( 54.7% ) yüksek olarak değerlendiriliyor.

Borcun Azaltılması: GBT şirketinin borç/öz sermaye oranının son 5 yılda azalıp azalmadığını belirlemek için yeterli veri yok.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: GBT şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: GBT tarihsel oranlara göre serbest nakit akışı büyümeye veya küçülmeye devam ederse yeterli nakit pistine sahip olup olmadığını belirlemek için yeterli veri yok.

Global Blood Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 2/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Global Blood Therapeutics (NASDAQ:GBT) Is Making Moderate Use Of Debt

Is Global Blood Therapeutics (NASDAQ:GBT) Using Too Much Debt?

Despite Lacking Profits Global Blood Therapeutics (NASDAQ:GBT) Seems To Be On Top Of Its Debt

Global Blood Therapeutics (NASDAQ:GBT) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Is Global Blood Therapeutics (NASDAQ:GBT) A Risky Investment?

Recent updates

Pfizer, Inc. and Global Blood Therapeutics, Inc. Sued over Alleged Sickle Cell Drug Side Effects

Global Blood Therapeutics, Inc.(NasdaqGS:GBT) dropped from NASDAQ Composite Index

Pfizer Inc. (NYSE:PFE) completed the acquisition of Global Blood Therapeutics, Inc. (NasdaqGS:GBT) from a group of shareholders.

Executive Vice President of Operations exercised options to buy US$2.0m worth of stock.

Global Blood Therapeutics expects to complete Pfizer deal in early October

Global Blood Therapeutics: Pfizer Acquisition Signals Increasing M/A Deals

CFO & Principal Accounting Officer recently sold US$1.9m worth of stock

CFO & Principal Accounting Officer notifies of intention to sell stock

Pfizer said to have had bidding war with Johnson & Johnson for Global Blood

Executive Vice President of Operations recently sold US$314k worth of stock

Pfizer Inc. (NYSE:PFE) entered into a definitive agreement to acquire Global Blood Therapeutics, Inc. (NasdaqGS:GBT) for $5 billion.

Pfizer Inc. (NYSE:PFE) entered into a definitive agreement to acquire Global Blood Therapeutics, Inc. (NasdaqGS:GBT) for $5 billion.

Price target increased to US$66.03

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

What Pfizer Is Getting Through The Acquisition Of Global Blood Therapeutics

Pfizer Reportedly in Advanced Talks to Buy Global Blood Therapeutics for $5 Billion

CFO & Principal Accounting Officer exercised options and sold US$69k worth of stock

Global Blood Therapeutics, Inc. to Report Q2, 2022 Results on Aug 08, 2022

MHRA Grants Marketing Authorization for Global Blood Therapeutics, Inc.'s Oxbryta (Voxelotor) for Use in Great Britain for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Age 12 Years and Older

Global Blood Therapeutics to expand access to its sickle cell disease treatment in Brazil

Global Blood Therapeutics, Inc. Initiates Phase 2/3 Clinical Trial of GBT601 in Patients with Sickle Cell Disease

GBT begins phase 2/3 clinical trial of GBT601 to treat sickle cell disease

Independent Director notifies of intention to sell stock

Global Blood Therapeutics: Powerhouse Of The Future

Global Blood Therapeutics, Inc. Presents Positive New Real-World Evidence Data at EHA2022 Congress Further Supporting Clinical Use of Oxbryta (Voxelotor) in Sickle Cell Disease

Global Blood Therapeutics, Inc.'s Inclacumab and GBT601 Receive U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for the Treatment of Sickle Cell Disease

Global Blood Therapeutics (NASDAQ:GBT) Is Making Moderate Use Of Debt

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Global Blood Therapeutics: Hitting A Growth Inflection

Chief Commercial Officer exercised options and sold US$54k worth of stock

No longer forecast to breakeven

Global Blood Therapeutics: Changing My Strategy After Recent Earnings

Consensus EPS estimates fall by 23%

Full year 2021 earnings: EPS exceeds analyst expectations

Is Global Blood Therapeutics (NASDAQ:GBT) Using Too Much Debt?

Global Blood Therapeutics, Inc. to Report Q4, 2021 Results on Feb 23, 2022

CFO & Principal Accounting Officer exercised options and sold US$132k worth of stock

CFO & Principal Accounting Officer exercised options and sold US$132k worth of stock

Global Blood Therapeutics, Inc. Announces Positive Early Access to Medicines Scheme Scientific Opinion

Global Blood Therapeutics, Inc. announces Oxbryta® (voxelotor) tablets for oral suspension

Forecast to breakeven in 2024

Global Blood Therapeutics: Revisiting A Stellar Grower

Global Blood Therapeutics, Inc. Receives Positive CHMP Opinion for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Aged 12 Years and Older

Global Blood Therapeutics, Inc. Presents Positive Results from Phase 1 Study of Gbt021601 in Patients with Sickle Cell Disease and Healthy Volunteers At ASH Annual Meeting and Exposition

GBT Presents Positive New Data on Oxbryta® (voxelotor) in Patients with Sickle Cell Disease at ASH Annual Meeting and Exposition

IBI Research On Global Blood Therapeutics: Galvanized For Growth

Third quarter 2021 earnings released: US$1.13 loss per share (vs US$0.97 loss in 3Q 2020)

Despite Lacking Profits Global Blood Therapeutics (NASDAQ:GBT) Seems To Be On Top Of Its Debt

Global Blood Therapeutics: It Might Be Time To Buy The Dip

Chief Commercial Officer exercised options and sold US$57k worth of stock

Independent Director recently sold US$145k worth of stock

Global Blood Therapeutics, Inc. Announces the U.S. Food and Drug Administration Accepts for Priority Review Supplemental New Drug Application for Oxbryta (Voxelotor)

President exercised options and sold US$140k worth of stock

Global Blood Therapeutics: Attempting To Classify The Investment

Second quarter 2021 earnings released: US$1.12 loss per share (vs US$0.86 loss in 2Q 2020)

CFO & Principal Accounting Officer exercised options and sold US$119k worth of stock

Global Blood Therapeutics, Inc. Provides Regulatory and Pipeline Updates in Sickle Cell Disease

Global Blood Therapeutics (NASDAQ:GBT) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Global Blood Therapeutics, Inc.(NasdaqGS:GBT) dropped from Russell Midcap Growth Index

Independent Director exercised options and sold US$59k worth of stock

Global Blood Therapeutics, Inc. Announces Voxelotor is First Sickle Cell Disease Treatment to Receive Promising Innovative Medicine Designation in the UK

Shareholders May Not Be So Generous With Global Blood Therapeutics, Inc.'s (NASDAQ:GBT) CEO Compensation And Here's Why

Global Blood Therapeutics, Inc. Announces New Data from the Phase 2a HOPE-KIDS 1 Study

Global Blood Therapeutics announces employment inducement grants

Consensus EPS estimates fall to -US$4.55

Global Blood Therapeutics: Increasing Specialization In SCD

Global Blood Therapeutics, Inc. Provides Revenue Guidance for the Second Quarter of 2021

First quarter 2021 earnings released: US$1.21 loss per share (vs US$1.20 loss in 1Q 2020)

Chief Commercial Officer exercised options and sold US$64k worth of stock

Global Blood Therapeutics, Inc. Appoints Alexis A. Thompson to the Board as A Class I Director